• 09 Feb 2024
• Admin
• News Article

Genprex Partners with Researchers to Expand Nonclinical Programs

Genprex Partners with Researchers to Expand Nonclinical Programs into New Therapeutic Indications

Genprex, Inc a clinical-stage innovator in gene therapy focusing on groundbreaking treatments for cancer and diabetes patients, has announced the expansion of its nonclinical programs into new areas through Sponsored Research Agreements and Material Transfer Agreements with various academic research partners. These collaborations aim to investigate TUSC2, the tumor suppressor gene utilized in Genprex's leading drug candidate, REQORSA (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The new research areas include ALK-positive lung cancer and additional undisclosed programs.

Genprex, stated, "We are advancing with a comprehensive research initiative to broaden the spectrum of potential targets for REQORSA in future clinical trials. Studies suggest that the TUSC2 gene, integral to REQORSA, may hold promise across various cancer types and potentially in treating other ailments. We are exploring avenues to address additional cancers where TUSC2 is frequently absent or inactive, delving into the fundamental biology of TUSC2 to optimize our REQORSA therapy. Furthermore, we are investigating the potential of NPRL2, another tumor suppressor gene, in cancer treatment utilizing our Oncoprex® Nanoparticle Delivery System."

Genprex's ONCOPREX® Nanoparticle Delivery System, a novel non-viral approach utilizing lipid nanoparticles, presents a promising avenue for delivering tumor suppressor genes, including TUSC2 and NPRL2, without the toxicity associated with viral delivery systems. This platform holds the potential to deliver a range of cancer-fighting genes alone or in combination with other therapies, offering hope for patients battling various cancer types.

REQORSA® (quaratusugene ozeplasmid) targets both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It comprises a plasmid expressing the TUSC2 gene encapsulated in non-viral nanoparticles made from lipid molecules (Genprex's ONCOPREX® Nanoparticle Delivery System) with a positive electrical charge. Administered intravenously, REQORSA specifically targets cancer cells, delivering the functioning TUSC2 gene while minimizing uptake by normal tissue. REQORSA's multimodal mechanism of action disrupts cancer cell signaling pathways, promotes programmed cell death (apoptosis), and modulates the immune response against cancer cells.

Genprex's strategy involves developing REQORSA in combination with existing therapies, aiming to enhance treatment outcomes for patients with NSCLC, SCLC, and potentially other cancers.